Neutrexin

Active Ingredient(s): Trimetrexate
FDA Approved: * December 17, 1993
Pharm Company: * MEDIMMUNE ONCOLOGY
Category: Immune System

Trimetrexate is a quinazoline derivative. It is a dihydrofolate reductase inhibitor.[1] Uses It has been used with leucovorin in treating pneumocystis pneumonia.[2] It has been investigated for use in treating leiomyosarcoma.[3] It is a methotrexate (MTX) analog that is active against transport-deficient MTX-resistant tumor cells that overcome the acquired and natural resistance to methotrexate. Other uses include skin lymphoma. [4&a... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.